YiChang HEC ChangJiang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
YiChang HEC ChangJiang Pharmaceutical has a total shareholder equity of CN¥8.7B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 23.9%. Its total assets and total liabilities are CN¥12.5B and CN¥3.8B respectively. YiChang HEC ChangJiang Pharmaceutical's EBIT is CN¥2.1B making its interest coverage ratio 30.4. It has cash and short-term investments of CN¥1.5B.
Key information
23.9%
Debt to equity ratio
CN¥2.07b
Debt
| Interest coverage ratio | 30.4x |
| Cash | CN¥1.52b |
| Equity | CN¥8.67b |
| Total liabilities | CN¥3.83b |
| Total assets | CN¥12.49b |
Recent financial health updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25
Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13Recent updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Financial Position Analysis
Short Term Liabilities: 1558's short term assets (CN¥5.5B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 1558's short term assets (CN¥5.5B) exceed its long term liabilities (CN¥1.3B).
Debt to Equity History and Analysis
Debt Level: 1558's net debt to equity ratio (6.3%) is considered satisfactory.
Reducing Debt: 1558's debt to equity ratio has reduced from 74.6% to 23.9% over the past 5 years.
Debt Coverage: 1558's debt is well covered by operating cash flow (21.9%).
Interest Coverage: 1558's interest payments on its debt are well covered by EBIT (30.4x coverage).